ETMONEY

ETMoney

close

Sucess

Great! You have sucessfully subscribed for newsletters for investments

Subcribed email:

  • Nippon India Pharma Fund

cross

logo

Link copied to clipboard

NAV as of(Aug 31, 2021)

315.08 1.43 % 1-D Change

Returns since inception

Returns

22.15% p.a.

Earn upto 0.84% extrareturns with Direct Plan

ETMONEYs Fund Report Card - Nippon India Pharma Fund

share Share

ETMONEY Rank

ranking

Not yet ranked

Performance Quality info

Very Gooddrop-arrow

Generated returns consistently

4/5

Increased returns for each unit of additional risk info

3/5

Downside Protection info

Very Gooddrop-arrow

Controlled losses during market corrections

3/5

Delivered returns without frequent ups and downs

4/5

Minimum SIP amount is ₹

of every month

Please select SIP day

Minimum Lumpsum amount is ₹

This fund is non-buyable

This fund is no longer available to invest

This fund vs

  • Category Avg
  • Gold

Show performance of:

Investment Mode
  • Monthly SIP
  • One-time (Lumpsum)

Investment Period
  • 1 month
  • 3 months
  • 6 months
  • 1 year
  • 3 years
  • 5 years
  • 10 years
  • Max

Scheme Details

About this Fund

Nippon India Pharma Fund-Growth is a Sectoral-Pharma mutual fund scheme from Nippon India Mutual Fund. This fund has been in existence for 17 yrs 3 m, having been launched on 10/05/2004. Nippon India Pharma Fund-Growth has ₹5,658 Crores worth of assets under management (AUM) as on 30/06/2021 and is medium-sized fund of its category. The fund has an expense ratio of 1.98%, which is higher than what most other Sectoral-Pharma funds charge.

  • Nippon India Pharma Fund-Growth returns of last 1-year are 47.96%. Since launch, it has delivered 22.14% average annual returns. The fund has doubled the money invested in it every 2 yrs.
  • Nippon India Pharma Fund-Growth schemes ability to deliver returns consistently is in-line with most funds of its category. Its ability to control losses in a falling market is average.
  • The fund has the majority of its money invested in Healthcare sectors. It has taken less exposure in Healthcare sectors compared to other funds in the category.
  • The funds top 5 holdings are in Sun Pharmaceutical Inds. Ltd., Divis Laboratories Ltd., Dr. Reddys Laboratories Ltd., Cipla Ltd., Aurobindo Pharma Ltd..

.....

investor_personality

Find your investor personality!

Answer a few simple questions and understand why you take the financial decisions you do.

warning

Investment Returns Calculator

  • Monthly SIP
  • One-time (Lumpsum)

of

for

  • 1 Month
  • 3 Months
  • 6 Months
  • 1 year
  • 3 years
  • 5 years
  • 10 years

Total investment Invested

Profit

Current value of investment Current value

You would have earned ₹ 1,001 in Direct Plan of this scheme

Total valueProfit
  • Absolute
  • Annualized

This fund

Category Average

Bank FD

Gold

Disclaimer: Products compared like fixed deposits may provide fixed guaranteed returns. Mutual Funds investments are subject to market risk, read all scheme related documents carefully. Past performance is not an indicator of future returns.

Latest Asset & Portfolio Allocation

as on Jul 31, 2021

  • Equity95.4%
  • Debt0%
  • Other4.6%
  • Top Stock Holdings
  • Allocation by Market Cap
  • Allocation by Sector

Top Stock Holdings

Sun Pharmaceutical Inds. Ltd. 10.4%

Divis Laboratories Ltd. 9.54%

Dr. Reddys Laboratories Ltd. 7.99%

  • Top Debt Holdings
  • Allocation by Credit Quality
  • Allocation by Instruments

Top Debt Holdings

Bifurcation by Holding is not available for this fund

Allocation by Credit Quality

Bifurcation by Credit Quality is not available for this fund

Allocation by Instruments

Comparison with sectoral-pharma Funds

as on Sep 01, 2021

Lowest
-0.42%

Highest
5.85%

Pick time period to see return

  • 1m
  • 3m
  • 6m
  • 1y
  • 3y
  • 5y

Sign-up for free to view funds trailing returns and ratings

Trailing Returns and Ranks

as on Sep 01, 2021

PeriodTrailing returnsCategory averageRank within category
1 month0.51%1.88%6 / 8
3 months7.86%8.84%6 / 8
6 months28.13%25.45%2 / 8
1 year46.21%42.73%2 / 8
3 years24.72%24.23%3 / 6
5 years17.02%13.48%1 / 4
10 years19.15%17.6%1 / 3

Riskometer

Level of Risk in the Scheme

Very

Investors understand that their principal will be at Very High risk

Nippon India Pharma Fund

EQUITY SECTORAL-PHARMA

Investment objective

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.

Performance Ratios

  • Std. Dev : 20.54
  • Alpha : 6.06
  • Beta : 0.88
  • Sharpe : 1.13
  • Sortino : 2.57

Nippon

Nippon India Mutual Fund

TOTAL AUM:

₹ 2,42,102 Crs

As on Jun 30, 2021

  • Email: customer_care@nipponindiamf.com
  • Phone: 022-68334800 / 18602660111
  • Address: Reliance Centre, 7th Floor, South Wing
    Off Western Express Highway
    Santacruz (East)
    Mumbai, 400055

0

Frequently asked questions

How are the returns of Nippon India Pharma Fund ?

The Nippon India Pharma Fund is a 17 yrs 3 m old fund and has delivered average annual returns of 22.14727925302111% since inception.

Nippon India Pharma Fund Returns

1-Year3-Year5-Year10-YearSince Inception
46.21%24.72%17.02%19.15%22.14727925302111%

NAV or Net Asset Value is the per-unit price of the Mutual Fund. The NAV of a Mutual Fund changes every day. It is calculated by taking the current value of the holdings of the fund at end of the day, subtracting the expenses, and dividing the value by the number of units issued to date.

The NAV of Nippon India Pharma Fund for Aug 31, 2021 is 315.08.

Nippon India Pharma Fund-Growth is the regular plan of the fund. For this plan of you pay 1.98%  as annual charges. On the other hand if you go for the direct plan available on ETMONEY, you pay 1.14%. Thats 0.84% less.

Regular plans charge more because when you buy them, the fund pays commission to the agent. This is an additional expense for the fund and to cover this expense, the fund takes a bigger share from the returns generated by your investments.

So, the lower annual cost of the direct plan means you will earn 0.84% if you opt for direct plan of Nippon India Pharma Fund

The Expense Ratio of a Mutual Fund is the annual charges you pay to the Mutual Fund company for managing your investments in that fund. The Expense Ratio is a percentage of Assets Under Management (AUM) and is taken from the returns generated by the fund. For this reason, a fund with a lower expense ratio is always better because a smaller part of the returns will be taken and that means more returns for you.

The Expense Ratio of the direct plan of Nippon India Pharma Fund is 1.98%. .

Redeeming your investments in Nippon India Pharma Fund is super easy. If you have invested in this fund via ETMONEY, just login into the app, go to the investment section and put the redemption request.

If you have invested in Nippon India Pharma Fund from anywhere else, you can go to the fund house website and put a request through it.

AUM or Asset Under Management is the total value of the assets held by a Mutual Fund scheme. For instance, for an equity Mutual Fund, the AUM will be the total value of its portfolios equity shares (plus any other asset it might have invested in). The AUM of the fund changes every day because the price of the underlying asset fluctuates daily. However, the Mutual Fund company doesnt update it every day. It is updated only at the end of the month and released within few days of the next month.

The AUM of the fund is a good indicator of its popularity. A fund with a high AUM means a lot of money has been invested in it, and investors like it. However, the AUM should never be the primary criteria while selecting a fund. There are funds with huge AUMs that continue to perform well despite their size.

The AUM of Nippon India Pharma Fund is ₹ 5,658 Crs.

The Nippon India Pharma Fund has invested the majority of its money in the stocks of the following companies -

CompanyPercentage of Portfolio
Sun Pharmaceutical Inds. Ltd.10.4%
Divis Laboratories Ltd.9.54%
Dr. Reddys Laboratories Ltd.7.99%
Cipla Ltd.7.81%
Aurobindo Pharma Ltd.7.78%
Lupin Ltd.6.65%
Gland Pharma Ltd.6.25%
Fortis Healthcare (India) Ltd5.14%
Thyrocare Technologies Ltd.4.36%
Apollo Hospitals Enterprise Ltd.4.28%

The Nippon India Pharma Fund has primarily invested in the following sectors

SectorPercentage of Portfolio
Healthcare95.23%
Others0.17%

Reach out

Find us at the office

Mcevilly- Liposky street no. 40, 55778 Tórshavn, Faroe Islands

Give us a ring

Maliek Elvis
+23 188 845 957
Mon - Fri, 7:00-15:00

Say hello